ArticleMedical oncology (Northwood, London, England)2025
Investigating the in-vitro and in-vivo potential of Eudrilus eugeniae coelomic fluid fractions on cancer cell lines: insights into mechanisms and therapeutic implications.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current cancer treatments, including surgery, radiotherapy, and chemotherapy, frequently have significant adverse effects, which restrict treatment options due to their toxicity. It is crucial to identify supplementary therapies using natural compounds that can inhibit tumor growth without causing severe side effects. This study explored the anti-cancer potential of earthworm coelomic fluid (ECF) protein (CF-P), non-protein (CF-NP), and crude (CF-C) from Eudrilus eugeniae against various human cancer cell lines (A549, MCF-7, MDA-MB-231, ME180, HEPG2, and HT-29). In vitro assays, such as MTT, cell cycle analysis, ROS analysis, apoptosis assays, and DAPI staining, revealed strong and variable cytotoxic effects of ECF fractions across different cell lines, with CF-P demonstrating the most substantial anti-cancer activity by inducing early G2/M cell cycle arrest and apoptosis more effectively than CF-C and CF-NP. In vivo studies using a DEN-induced hepatocellular carcinoma (HCC) mouse model indicated that CF treatments significantly enhanced body weight, alleviating cancer-induced cachexia, and reduced liver weight, with CF-P exhibiting the most notable therapeutic effects. Haematological and biochemical analyses showed improved RBC counts, decreased leukocytosis, and normalized liver and renal function markers. Histopathological assessments of liver and lung tissues revealed fewer neoplastic nodules, reduced necrosis, and improved tissue structure, underscoring the protective effects of CF fractions. These findings suggest that CF fractions, particularly CF-P, have potential as cytoprotective and anti-tumor agents in cancer therapy. This study provides novel insights into the in-vitro and in-vivo anti-cancer activity of non-protein, protein, and crude Eudrilus eugeniae coelomic fluid across various cancer cells in vitro, shedding light on their potential mechanisms of action.
Indexed as
Identifiers
41385129What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.